title: T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
abstract: We recently showed that vaccination with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein (CHP-NY-ESO-1) elicited antibody responses in 9 of 9 patients vaccinated in a clinical trial. In this study, we performed T cell immunomonitoring and analyzed tumor responses in these patients. To evaluate CD4 and CD8 T cell responses, an IFN-gamma secretion assay was used. The assay showed low background and was sensitive for detecting antigen-specific T cells. An increase in the CD4 T cell response was observed in 2 of 2 initially sero-positive and 5 of 7 initially sero-negative patients after vaccination. An increase in the CD8 T cell response was also observed in 2 of 2 sero-positive and 5 of 7 sero-negative patients after vaccination. Analysis of peptides recognized by CD4 and CD8 T cells revealed two dominant NY-ESO-1 regions, 73-114 and 121-144. Tumor responses were observed in 3 esophageal cancer patients and a malignant melanoma patient. In 3 of 4 prostate cancer patients, prostate-specific antigen (PSA) values stabilized during the course of vaccination. The use of whole protein, containing multiple CD4 and CD8 epitopes, may be beneficial for cancer vaccines to prevent tumors from evading the immune response.
authors: Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Shikata-cho, Okayama, Japan.
authors: Akiko
authors: A
authors: Uenaka
authors: Hisashi
authors: H
authors: Wada
authors: Midori
authors: M
authors: Isobe
authors: Takashi
authors: T
authors: Saika
authors: Kazuhide
authors: K
authors: Tsuji
authors: Eiichi
authors: E
authors: Sato
authors: Shuichiro
authors: S
authors: Sato
authors: Yuji
authors: Y
authors: Noguchi
authors: Ryohei
authors: R
authors: Kawabata
authors: Takushi
authors: T
authors: Yasuda
authors: Yuichiro
authors: Y
authors: Doki
authors: Hiromi
authors: H
authors: Kumon
authors: Keiji
authors: K
authors: Iwatsuki
authors: Hiroshi
authors: H
authors: Shiku
authors: Morito
authors: M
authors: Monden
authors: Achim A
authors: AA
authors: Jungbluth
authors: Gerd
authors: G
authors: Ritter
authors: Roger
authors: R
authors: Murphy
authors: Eric
authors: E
authors: Hoffman
authors: Lloyd J
authors: LJ
authors: Old
authors: Eiichi
authors: E
authors: Nakayama
mesh_terms: D000368:Aged; D000917:Antibody Formation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002784:Cholesterol / Q000008:administration & dosage* / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000009:adverse effects; D005260:Female; D005936:Glucans / Q000008:administration & dosage* / Q000494:pharmacology; D015234:HLA-A Antigens / Q000276:immunology; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D010455:Peptides / Q000276:immunology; D014611:Vaccination
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D005936:Glucans; D015234:HLA-A Antigens; D008565:Membrane Proteins; D010455:Peptides; D007371:Interferon-gamma; C009109:pullulan; D002784:Cholesterol